{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:23:50Z","timestamp":1772781830514,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.vaccine.2012.01.001","type":"journal-article","created":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T15:40:03Z","timestamp":1326210003000},"page":"1813-1822","source":"Crossref","is-referenced-by-count":28,"title":["Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening"],"prefix":"10.1016","volume":"30","author":[{"given":"Veerle M.H.","family":"Coup\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes A.","family":"Bogaards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris J.L.M.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Berkhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"April (7)","key":"10.1016\/j.vaccine.2012.01.001_bib0005","first-page":"1017","article-title":"Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection","volume":"164","author":"Franco","year":"2001","journal-title":"CMAJ"},{"issue":"April (9518)","key":"10.1016\/j.vaccine.2012.01.001_bib0010","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"May (19)","key":"10.1016\/j.vaccine.2012.01.001_bib0015","first-page":"1915","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"The Future II Study Group","year":"2007","journal-title":"N Engl J Med"},{"issue":"April (16)","key":"10.1016\/j.vaccine.2012.01.001_bib0020","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1016\/j.vaccine.2007.01.016","article-title":"Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening","volume":"25","author":"Adams","year":"2007","journal-title":"Vaccine"},{"issue":"August (Suppl. 3)","key":"10.1016\/j.vaccine.2012.01.001_bib0025","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.vaccine.2006.05.061","article-title":"Issues in planning cervical cancer screening in the era of HPV vaccination","volume":"24","author":"Franco","year":"2006","journal-title":"Vaccine"},{"issue":"October (43)","key":"10.1016\/j.vaccine.2012.01.001_bib0030","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1016\/j.vaccine.2009.07.026","article-title":"Screening, prevention and treatment of cervical cancer\u2014a global and regional generalized cost-effectiveness analysis","volume":"27","author":"Ginsberg","year":"2009","journal-title":"Vaccine"},{"issue":"April (8)","key":"10.1016\/j.vaccine.2012.01.001_bib0035","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2012.01.001_bib0040","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jnci\/djn019","article-title":"Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination","volume":"100","author":"Goldhaber-Fiebert","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"August (6)","key":"10.1016\/j.vaccine.2012.01.001_bib0045","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.290.6.781","article-title":"Potential health and economic impact of adding a human papillomavirus vaccine to screening programs","volume":"290","author":"Kulasingam","year":"2003","journal-title":"JAMA"},{"issue":"February","key":"10.1016\/j.vaccine.2012.01.001_bib0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-7547-6-4","article-title":"Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis","volume":"6","author":"Kulasingam","year":"2008","journal-title":"Cost Eff Resour Alloc"},{"issue":"September (Suppl. 5)","key":"10.1016\/j.vaccine.2012.01.001_bib0055","doi-asserted-by":"crossref","first-page":"F46","DOI":"10.1016\/j.vaccine.2008.02.039","article-title":"Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis","volume":"26","author":"Rogoza","year":"2008","journal-title":"Vaccine"},{"issue":"August (37)","key":"10.1016\/j.vaccine.2012.01.001_bib0060","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1016\/j.vaccine.2009.06.043","article-title":"How to screen for cervical cancer after HPV16\/18 vaccination in The Netherlands","volume":"27","author":"Coupe","year":"2009","journal-title":"Vaccine"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2012.01.001_bib0065","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2012.01.001_bib0070","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1086\/597308","article-title":"Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types","volume":"199","author":"Herrero","year":"2009","journal-title":"J Infect Dis"},{"issue":"July (9686)","key":"10.1016\/j.vaccine.2012.01.001_bib0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2012.01.001_bib0080","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/jnci\/djp119","article-title":"Broad-spectrum human papillomavirus vaccines: new horizons but one step at a time","volume":"101","author":"Bosch","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.01.001_bib0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1086\/317638","article-title":"A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types","volume":"183","author":"Liaw","year":"2001","journal-title":"J Infect Dis"},{"issue":"June (9576)","key":"10.1016\/j.vaccine.2012.01.001_bib0090","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"issue":"May (19)","key":"10.1016\/j.vaccine.2012.01.001_bib0095","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"June (9580)","key":"10.1016\/j.vaccine.2012.01.001_bib0100","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"December (11)","key":"10.1016\/j.vaccine.2012.01.001_bib0105","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"issue":"August (3)","key":"10.1016\/j.vaccine.2012.01.001_bib0110","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2012.01.001_bib0115","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/jcp.2003.011841","article-title":"The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996","volume":"57","author":"Bulk","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.vaccine.2012.01.001_bib0120","series-title":"WHO guide for standardization of economic evaluations of immunization programmes","year":"2008"},{"key":"10.1016\/j.vaccine.2012.01.001_bib0125","series-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","year":"2005"},{"issue":"November (48)","key":"10.1016\/j.vaccine.2012.01.001_bib0190","doi-asserted-by":"crossref","first-page":"8929","DOI":"10.1016\/j.vaccine.2011.09.055","article-title":"The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands","volume":"29","author":"Bogaards","year":"2011","journal-title":"Vaccine"},{"issue":"November (9)","key":"10.1016\/j.vaccine.2012.01.001_bib0130","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.25211","article-title":"The health and economic effects of HPV DNA screening in The Netherlands","volume":"127","author":"Berkhof","year":"2010","journal-title":"Int J Cancer"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2012.01.001_bib0135","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1473-3099(10)70004-9","article-title":"Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?","volume":"10","author":"Bauch","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"July (5)","key":"10.1016\/j.vaccine.2012.01.001_bib0140","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ijc.11141","article-title":"Meta-analysis of social inequality and the risk of cervical cancer","volume":"105","author":"Parikh","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2012.01.001_bib0145","first-page":"369","article-title":"Socioeconomic status and cancer screening","volume":"138","author":"Segnan","year":"1997","journal-title":"IARC Sci Publ"},{"issue":"June","key":"10.1016\/j.vaccine.2012.01.001_bib0150","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1006\/pmed.2001.0844","article-title":"Reasons women do not attend screening for cervical cancer: a population-based study in Sweden","volume":"32","author":"Eaker","year":"2001","journal-title":"Prev Med"},{"issue":"April 26","key":"10.1016\/j.vaccine.2012.01.001_bib0155","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1471-2458-11-264","article-title":"Factors associated with non-attendance, opportunistic attendance and reminded attendance to cervical screening in an organized screening program: a cross-sectional study of 12,058 Norwegian women","volume":"11","author":"Hansen","year":"2011","journal-title":"BMC Public Health"},{"issue":"November (9601)","key":"10.1016\/j.vaccine.2012.01.001_bib0160","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(07)61450-0","article-title":"Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial","volume":"370","author":"Bulkmans","year":"2007","journal-title":"Lancet"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2012.01.001_bib0165","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.bjc.6604162","article-title":"Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening","volume":"98","author":"Coupe","year":"2008","journal-title":"Br J Cancer"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2012.01.001_bib0170","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/infdis\/jiq131","article-title":"Persistence of concurrent infections with multiple human papillomavirus types: a population-based cohort study","volume":"203","author":"Campos","year":"2011","journal-title":"J Infect Dis"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2012.01.001_bib0175","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/infdis\/jiq139","article-title":"Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease","volume":"203","author":"Chaturvedi","year":"2011","journal-title":"J Infect Dis"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2012.01.001_bib0180","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/infdis\/jiq146","article-title":"Multiple human papillomavirus infections: the exception or the rule?","volume":"203","author":"Plummer","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.01.001_bib0185","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/1055-9965.EPI-09-0983","article-title":"Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys","volume":"19","author":"Vaccarella","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:50:17Z","timestamp":1543279817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12000023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0264410X12000023"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.01.001","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}